A number of other research analysts have also recently weighed in on the stock. BTIG Research raised their price objective on shares of Hologic from $46.00 to $54.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Raymond James raised shares of Hologic from a “market perform” rating to an “outperform” rating and set a $62.00 price objective for the company in a research note on Wednesday, June 3rd. UBS Group dropped their price objective on shares of Hologic from $58.00 to $52.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. SVB Leerink raised shares of Hologic from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $41.00 to $62.00 in a research note on Thursday, April 30th. Finally, Needham & Company LLC assumed coverage on shares of Hologic in a research note on Tuesday, June 2nd. They set a “buy” rating and a $60.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $56.06.
Shares of NASDAQ:HOLX traded down $1.86 on Tuesday, reaching $50.15. 72,843 shares of the company were exchanged, compared to its average volume of 2,760,014. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 1.32. Hologic has a 1-year low of $26.49 and a 1-year high of $55.25. The firm has a market cap of $13.71 billion, a price-to-earnings ratio of 21.84, a price-to-earnings-growth ratio of 3.31 and a beta of 1.44. The company has a 50-day moving average of $50.90 and a 200-day moving average of $48.72.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, April 29th. The medical equipment provider reported $0.57 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.57. Hologic had a net margin of 18.53% and a return on equity of 30.49%. The firm had revenue of $756.10 million during the quarter, compared to the consensus estimate of $756.10 million. During the same period last year, the firm posted $0.58 EPS. As a group, analysts forecast that Hologic will post 2.25 earnings per share for the current year.
In other news, General Counsel John M. Griffin sold 4,906 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.00, for a total transaction of $245,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter J. Valenti III sold 10,493 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $51.82, for a total transaction of $543,747.26. The disclosure for this sale can be found here. Insiders have sold a total of 238,345 shares of company stock valued at $12,185,194 over the last three months. Corporate insiders own 1.00% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Dean Capital Investments Management LLC grew its stake in shares of Hologic by 68.0% during the 4th quarter. Dean Capital Investments Management LLC now owns 6,744 shares of the medical equipment provider’s stock valued at $352,000 after buying an additional 2,730 shares during the period. AJO LP grew its stake in shares of Hologic by 45.9% during the 4th quarter. AJO LP now owns 2,498,232 shares of the medical equipment provider’s stock valued at $130,432,000 after buying an additional 785,593 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Hologic by 2.5% during the 4th quarter. Renaissance Technologies LLC now owns 838,118 shares of the medical equipment provider’s stock valued at $43,758,000 after acquiring an additional 20,050 shares in the last quarter. CSat Investment Advisory L.P. lifted its holdings in shares of Hologic by 219.1% during the 4th quarter. CSat Investment Advisory L.P. now owns 2,604 shares of the medical equipment provider’s stock valued at $136,000 after acquiring an additional 1,788 shares in the last quarter. Finally, Forsta AP Fonden acquired a new position in shares of Hologic during the 1st quarter valued at $1,499,000. 92.45% of the stock is owned by institutional investors.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: How does the Beige Book influence monetary policy?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.